Technical Analysis for MORF - Morphic Holding, Inc.

Grade Last Price % Change Price Change
D 35.20 2.36% 0.81
MORF closed up 2.36 percent on Thursday, March 28, 2024, on 65 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Stochastic Buy Signal Bullish 2.36%
Gapped Up Strength 2.36%
Oversold Stochastic Weakness 2.36%
Inside Day Range Contraction 7.38%
Gapped Up Strength 7.38%
Oversold Stochastic Weakness 7.38%
Stochastic Reached Oversold Weakness 9.49%

   Recent Intraday Alerts

Alert Time
20 DMA Resistance about 6 hours ago
Up 3% about 7 hours ago
Rose Above 20 DMA about 7 hours ago
60 Minute Opening Range Breakout about 7 hours ago
Up 2% about 7 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Gastrointestinal Cancers Integrin

Is MORF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 63.0825
52 Week Low 19.345
Average Volume 526,559
200-Day Moving Average 38.07
50-Day Moving Average 34.75
20-Day Moving Average 35.25
10-Day Moving Average 33.89
Average True Range 1.83
RSI (14) 51.69
ADX 22.74
+DI 19.09
-DI 22.49
Chandelier Exit (Long, 3 ATRs) 34.52
Chandelier Exit (Short, 3 ATRs) 37.26
Upper Bollinger Bands 38.88
Lower Bollinger Band 31.62
Percent B (%b) 0.49
BandWidth 20.57
MACD Line -0.44
MACD Signal Line -0.28
MACD Histogram -0.1666
Fundamentals Value
Market Cap 1.75 Billion
Num Shares 49.7 Million
EPS -3.29
Price-to-Earnings (P/E) Ratio -10.70
Price-to-Sales 296.69
Price-to-Book 2.73
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.78
Resistance 3 (R3) 37.60 36.57 37.35
Resistance 2 (R2) 36.57 35.91 36.66 37.21
Resistance 1 (R1) 35.88 35.50 36.23 36.06 37.06
Pivot Point 34.85 34.85 35.02 34.94 34.85
Support 1 (S1) 34.16 34.19 34.51 34.34 33.34
Support 2 (S2) 33.13 33.78 33.22 33.19
Support 3 (S3) 32.44 33.13 33.05
Support 4 (S4) 32.62